Novavax (NVAX) Cash from Investing Activities Growth (3y) (2013 - 2026)
Novavax (NVAX) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Novavax | 1.23 Bn | 440.77 Mn | 108.82 Mn | -6.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.38% |
| Dec 31, 2025 | 43.07% |
| Sep 30, 2025 | -66.61% |
| Jun 30, 2025 | 86.82% |
| Mar 31, 2025 | -63.33% |
| Dec 31, 2024 | 121.04% |
| Sep 30, 2024 | 66.53% |
| Jun 30, 2024 | -206.84% |
| Mar 31, 2024 | -27.06% |
| Dec 31, 2023 | 33.68% |
| Sep 30, 2023 | 43.27% |
| Jun 30, 2023 | 65.43% |
| Mar 31, 2023 | 25.83% |
| Dec 31, 2022 | -367.46% |
| Sep 30, 2022 | -53.86% |
| Jun 30, 2022 | -141.83% |
| Mar 31, 2022 | -42.59% |
| Dec 31, 2021 | -32.74% |
| Sep 30, 2021 | -52.18% |
| Jun 30, 2021 | 35.60% |